- Conditions
- Narcolepsy, Idiopathic Hypersomnia
- Interventions
- Xywav, Placebo
- Drug · Other
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Daphne, Alabama + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 721–744
of 8,003
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Azacitidine, Tagraxofusp-erzs
- Drug · Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Los Angeles, California • San Francisco, California
- Conditions
- HIV
- Interventions
- DV901-NP, DV902-NP, CH505 TF mRNA-gp160, CH505 w24 mRNA-gp160, ACU-026-001-1
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 8
- States / cities
- San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
- Conditions
- Prostate Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Bethesda, Maryland
- Conditions
- GIST
- Interventions
- Inlexisertib, Ripretinib
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Miami, Florida • Worcester, Massachusetts + 7 more
- Conditions
- Solid Tumor, Cancer, Carcinoma
- Interventions
- KHK2455, Mogamulizumab
- Drug
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Albuquerque, New Mexico • Houston, Texas
- Conditions
- Malignant Solid Tumor, Lymphomas, Multiple Myeloma
- Interventions
- AV-299, AV-299 + erlotinib
- Biological
- Lead sponsor
- AVEO Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Columbus, Ohio • San Antonio, Texas
- Conditions
- Healthy Volunteers
- Interventions
- REGN727, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Cognitive Impairment
- Interventions
- Single Dose of VU319, Single Dose Placebo, Fed State, Fasted State, Dose Escalation of VU319, Placebo Dose Escalation
- Drug · Other
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Neoplasms, Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 4 Weeks and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy
- Interventions
- Esketamine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- JNJ-64264681
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Graft-versus-host Disease
- Interventions
- Neihulizumab, 3 mg/kg, Neihulizumab, 6 mg/kg, Neihulizumab, 9 mg/kg, Neihulizumab
- Biological · Drug
- Lead sponsor
- Sameem M. Abedin, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Thromboembolism of Vein VTE in Colorectal Cancer, Thromboembolism of Vein in Pancreatic Cancer, Thromboembolism of Vein in Non-small Cell Lung Cancer
- Interventions
- Isoquercetin
- Drug
- Lead sponsor
- Jeffrey Zwicker, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Sacramento, California • West Haven, Connecticut + 7 more
- Conditions
- Hepatocellular Carcinoma, Biliary Tract Cancer
- Interventions
- RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy
- Biological
- Lead sponsor
- Replimune, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • La Jolla, California • Miami, Florida + 9 more
- Conditions
- Prostate Cancer
- Interventions
- Not listed
- Lead sponsor
- Life Length SL
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 509 participants
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Hialeah, Florida • Houston, Texas
- Conditions
- Solid Tumors
- Interventions
- Genz-644282 (28-day dosing schedule), Genz-644282 (21-day dosing schedule)
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 1 more
- Conditions
- Multiple Myeloma
- Interventions
- VELCADE™
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Glioblastoma
- Interventions
- Treatment Period 1, Treatment Period 2, Treatment Period 3, Treatment Period 4a
- Drug
- Lead sponsor
- SignPath Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Interventions
- Venetoclax, Obinutuzumab, Acalabrutinib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 4
- States / cities
- Stamford, Connecticut • Boston, Massachusetts • Providence, Rhode Island
- Conditions
- Kidney Cancer
- Interventions
- MDX 1411
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • Detroit, Michigan • Las Vegas, Nevada + 4 more
- Conditions
- Non-small Cell Lung Cancer, NSCLC
- Interventions
- AMG 160
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Sex Work, Pre-Exposure Prophylaxis
- Interventions
- C-PrEP+
- Other
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, CD20 Positive, Diffuse Large B-Cell Lymphoma Unclassifiable, Intravascular Large B-Cell Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab, Prednisone, Quality-of-Life Assessment, Rituximab, Vincristine Sulfate
- Drug · Biological · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Lake Forest, Illinois • Warrenville, Illinois